D. Skarlos

944 total citations
51 papers, 743 citations indexed

About

D. Skarlos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, D. Skarlos has authored 51 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in D. Skarlos's work include Lung Cancer Treatments and Mutations (20 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Research Studies (10 papers). D. Skarlos is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Research Studies (10 papers). D. Skarlos collaborates with scholars based in Greece, United Kingdom and Spain. D. Skarlos's co-authors include George Fountzilas, P. Kosmidis, Gerasimos Aravantinos, N. Mylonakis, E. Samantas, Meletios Α. Dimopoulos, Nikolaos Pavlidis, Haralabos P. Kalofonos, F Apostolopoulou and Dimitrios Bafaloukos and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

D. Skarlos

50 papers receiving 717 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Skarlos Greece	17	484	284	172	155	110	51	743
William H. Isacoff United States	16	499 1.0×	223 0.8×	152 0.9×	227 1.5×	138 1.3×	25	804
P H de Mulder Netherlands	13	322 0.7×	145 0.5×	201 1.2×	272 1.8×	39 0.4×	18	754
T. Geldart United Kingdom	15	293 0.6×	178 0.6×	202 1.2×	211 1.4×	67 0.6×	40	642
P. Clouet France	8	497 1.0×	421 1.5×	122 0.7×	208 1.3×	95 0.9×	10	869
Daniel Rauch Switzerland	20	711 1.5×	385 1.4×	149 0.9×	221 1.4×	89 0.8×	53	1.1k
Raffaele Pingitore Italy	13	191 0.4×	195 0.7×	156 0.9×	127 0.8×	74 0.7×	26	518
Iwona Skoneczna Poland	9	403 0.8×	236 0.8×	162 0.9×	741 4.8×	69 0.6×	16	956
Martin D. Phillips United States	12	349 0.7×	275 1.0×	153 0.9×	150 1.0×	35 0.3×	16	978
M. Morse United States	11	508 1.0×	358 1.3×	164 1.0×	539 3.5×	24 0.2×	22	1.0k
N. Vardakis Greece	17	629 1.3×	416 1.5×	163 0.9×	94 0.6×	31 0.3×	33	762

Countries citing papers authored by D. Skarlos

Since Specialization

Citations

This map shows the geographic impact of D. Skarlos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Skarlos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Skarlos more than expected).

Fields of papers citing papers by D. Skarlos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Skarlos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Skarlos. The network helps show where D. Skarlos may publish in the future.

Co-authorship network of co-authors of D. Skarlos

This figure shows the co-authorship network connecting the top 25 collaborators of D. Skarlos. A scholar is included among the top collaborators of D. Skarlos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Skarlos. D. Skarlos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kosmidis, P., Haralabos P. Kalofonos, C. Christodoulou, et al.. (2007). Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Annals of Oncology. 19(1). 115–122. 46 indexed citations

Stathopoulos, George P., N. Malamos, Gerasimos Aravantinos, et al.. (2006). Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer. Cancer Chemotherapy and Pharmacology. 60(1). 123–128. 10 indexed citations

Xiros, Nikolaos I., Theofanis Economopoulos, G.F. Samelis, et al.. (2005). Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Annals of Oncology. 16(5). 773–779. 13 indexed citations

Stathopoulos, George P., J. Stathopoulos, D. Skarlos, et al.. (2005). Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer Chemotherapy and Pharmacology. 57(6). 796–800. 12 indexed citations

Pectasides, D., Melina Pectasides, Dimitrios Farmakis, et al.. (2004). Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study. Annals of Oncology. 15(3). 493–497. 75 indexed citations

Bafaloukos, Dimitrios, C. Papadimitriou, Helena Linardou, et al.. (2004). Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. British Journal of Cancer. 91(9). 1639–1644. 12 indexed citations

Christodoulou, Christos, et al.. (2002). Effectiveness of the MSC Cold Cap System in the Prevention of Chemotherapy-Induced Alopecia. Oncology. 62(2). 97–102. 25 indexed citations

Dimopoulos, Meletios Α., Haralabos P. Kalofonos, C. Nicolaides, et al.. (2002). Vinblastine and Interferon-Gamma Combination with and without 13-Cis Retinoic Acid for Patients with Advanced Renal Cell Carcinoma. Oncology. 63(2). 130–138. 5 indexed citations

Pectasides, D., Haralabos P. Kalofonos, Epaminontas Samantas, et al.. (2001). An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.. PubMed. 21(4B). 3005–10. 17 indexed citations

10.

Tsavaris, N., D. Skarlos, Gerasimos Aravantinos, et al.. (2000). Combined Treatment with Low-Dose Interferon plus Vinblastine Is Associated with Less Toxicity Than Conventional Interferon Monotherapy in Patients with Metastatic Renal Cell Carcinoma. Journal of Interferon & Cytokine Research. 20(8). 685–690. 5 indexed citations

11.

Samantas, E., Haralabos P. Kalofonos, Helena Linardou, et al.. (2000). Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer. Annals of Oncology. 11(11). 1395–1397. 22 indexed citations

12.

Skarlos, D., Dimitrios Pectasides, N. Pavlidis, et al.. (1999). Weekly Alternating Non-Cross-Resistant Chemotherapy for Small Cell Lung Cancer With a Good Prognosis. American Journal of Clinical Oncology. 22(1). 87–93. 3 indexed citations

13.

Bafaloukos, Dimitrios, Gerasimos Aravantinos, George Samonis, et al.. (1999). Carboplatin, Methotrexate and 5-Fluorouracil in Combination with Medroxyprogesterone Acetate (JMF-M) in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Hellenic Cooperative Oncology Group Study. Oncology. 56(3). 198–201. 18 indexed citations

14.

Pectasides, D., Gerasimos Aravantinos, A. Visvikis, et al.. (1999). Platinum-Based Chemotherapy of Primary Extragonadal Germ Cell Tumours: The Hellenic Cooperative Oncology Group Experience. Oncology. 57(1). 1–9. 9 indexed citations

15.

Aravantinos, Gerasimos, D. Skarlos, P. Kosmidis, et al.. (1997). A phase II study of paclitaxel in platinum pretreated ovarian cancer. A hellenic cooperative oncology group study. European Journal of Cancer. 33(1). 160–163. 10 indexed citations

16.

Kosmidis, P., N. Mylonakis, George Fountzilas, et al.. (1997). Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study. Annals of Oncology. 8(7). 697–699. 29 indexed citations

17.

Kosmidis, P., C. Bacoyiannis, George Fountzilas, et al.. (1997). 5-Fluorouracil, interferon-α-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Annals of Oncology. 8(4). 373–378. 9 indexed citations

18.

Kosmidis, P., Νicolas Tsavaris, D. Skarlos, et al.. (1996). Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.. Journal of Clinical Oncology. 14(10). 2682–2687. 35 indexed citations

19.

Sivolapenko, Gregory, Κωνσταντίνος Κωνσταντινίδης, Dimitrios Pectasides, et al.. (1995). Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. The Lancet. 346(8991-8992). 1662–1666. 38 indexed citations

20.

Malamitsi, Julia, Alexandra D. Varvarigou, S.C. Archimandritis, et al.. (1994). Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody. Cell Biophysics. 24-25(1-3). 75–81. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact